Loading…
Xiamen-based global producer of natural vitamin E and other nutrition ingredients for food and supplement makers.
Xiamen-based global producer of natural vitamin E and other nutrition ingredients for food and supplement makers.
Extracts natural vitamin E from by-products of soybean-oil refining, so input costs follow edible-oil processing, and sells it by the tonne to supplement, food and feed makers. Its prices are shaped by competition from cheaper synthetic vitamin E, which a few large producers supply.
In one line: A Chinese DSM-Firmenich nutrition-ingredients unit.
Moat: narrow (scale, process know-how). One of the larger global natural vitamin E producers with integrated extraction know-how.
Headquarters: Xiamen, China · Employees: 2,184
Size Xiamen Kingdomway (002626.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.58B, the 1561st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥17.45 on 6 Nov 2026.
Performance Over six months the shares gained 14.7%, against -4.8% for the median peer and -16.4% for the China market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue fell 3.0% over the last twelve months (peer median +4.1%); the operating margin is 11.0% (peer median 9.9%).
Valuation It trades at 30.0× forward earnings against a peer median of 23.2× (4th most expensive of 13).
Capital Return on invested capital runs 1.7 points above its cost of capital (5.9% WACC).
Next results Next results expected around 14 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.40B | CN¥3.36B | CN¥3.24B | CN¥3.10B | CN¥3.00B |
| Revenue growth | — | +4% | +5% | +3% | — |
| Gross profit | CN¥1.44B | CN¥1.24B | CN¥1.16B | CN¥1.05B | CN¥1.11B |
| EBITDA | n/a | CN¥678M | CN¥662M | CN¥541M | CN¥616M |
| Net income | CN¥233M | CN¥340M | CN¥342M | CN¥277M | CN¥257M |
| Free cash flow | -CN¥402M | CN¥343M | CN¥165M | CN¥413M | CN¥536M |
| Capital expenditure | CN¥775M | CN¥230M | CN¥365M | CN¥252M | CN¥162M |
| Total debt | CN¥2.39B | CN¥2.53B | CN¥1.43B | CN¥916M | CN¥1.13B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Xiamen Kingdomway 002626.SZ | $1.58B | +15% | -3% | 11% | 30.0× | n/a |
| DSM-Firmenich DSFIR.AS | $29.5B | +62% | -45% | 8% | 30.1× | 24.3% |
| Basf BAS.DE | $52.6B | +2% | -4% | 7% | 16.8× | 5.7% |
| Zhejiang NHU 002001.SZ | $12.3B | -23% | +11% | 33% | 9.9× | -7.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002626.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.5% | +3.6% | 5th highest of 21 |
| 6-month return | +14.7% | -4.8% | 6th highest of 20 |
| Distance from 52-week high | -18.9% | -22.9% | 9th highest of 21 |
| Revenue growth (TTM) | -3.0% | +4.1% | 8th lowest of 20 |
| Operating margin | 11.0% | 9.9% | 10th highest of 20 |
| Forward P/E | 30.0× | 23.2× | 4th most expensive of 13 |
| ROIC minus cost of capital | +1.7 pp | +1.2 pp | 9th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Xiamen Kingdomway 002626.SZ | China | $1.58B | +15% | -3% | 11% | 30.0× | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.58B | +40% | +17% | 18% | 63.7× | 37.6% | +16.6% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.58B | -4% | +16% | 9% | 29.0× | n/a | n/a |
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | n/a | n/a | n/a |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.56B | -5% | +4% | 9% | 18.5× | -5.8% | +1.9% |
| Indegene INDGN.NS | India | $1.56B | +15% | +36% | 12% | 27.5× | 29.6% | +29.4% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | n/a | -4.1% | +0.2% |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.55B | +53% | -6% | -19% | n/a | 49.9% | -13.2% |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 27.9× | 39.6% | +359.6% |
| Nanobiotix NANO.PA | France | $1.54B | -42% | -77% | -392% | n/a | n/a | n/a |
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 16.2× | -4.5% | +6.8% |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.53B | -17% | +2% | -2% | 42.9× | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.52B | +22% | +16% | -64% | n/a | n/a | n/a |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 9.2× | -15.1% | +13.5% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.67B | -14% | -13% | 6% | 13.2× | -6.0% | -5.6% |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 13.0× | -8.5% | +4.6% |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.67B | +1% | -4% | 15% | 47.5× | 6.7% | -4.3% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| NATCO Pharma NATCOPHARM.NS | India | $1.68B | -30% | -21% | 25% | 18.8× | 15.3% | +19.0% |
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | n/a | n/a | n/a |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.69B | -25% | +31% | 10% | n/a | 49.3% | +23.0% |